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Abstract
Induced pluripotent stem (iPS) cells can be generated from somatic cells by co-
expression of four transcription factors: Sox2, Oct4, Klf4, and c-Myc. However,
the low efﬁciency in generating iPS cells and the tendency of tumorigenesis hin-
der the therapeutic applications for iPS cells in treatment of human diseases.
To this end, it remains largely unknown how the iPS process is subjected to
regulation by upstream signaling pathway(s). Here, we report that Akt regulates
the iPS process by modulating posttranslational modiﬁcations of these iPS fac-
tors in both direct and indirect manners. Speciﬁcally, Akt directly phosphory-
lates Oct4 to modulate the Oct4/Sox2 heterodimer formation. Furthermore,
Akt either facilitates the p300-mediated acetylation of Oct4, Sox2, and Klf4, or
stabilizes Klf4 by inactivating GSK3, thus indirectly modulating stemness. As
tumorigenesis shares possible common features and mechanisms with iPS, our
study suggests that Akt inhibition might serve as a cancer therapeutic approach
to target cancer stem cells.
Introduction
Embryonic stem (ES) cells are derived from the inner
cell mass of mammalian blastocysts and have been
demonstrated to maintain pluripotency [1, 2]. The plu-
ripotent potential of human ES cells has been proposed
to be beneﬁcial in the treatment of various human dis-
eases including Parkinson’s disease, spinal cord injury,
and diabetes [3, 4]. However, the therapeutic use of ES
cells requires a comprehensive understanding of the
molecular mechanisms that control the proliferation and
differentiation of ES cells [5, 6]. More importantly, ethi-
cal controversy regarding the use of human embryos also
prevents its therapeutic application. To overcome this
issue, coexpression of Oct4, Sox2, Klf4, and Nanog or
c-Myc in normal mouse or human ﬁbroblasts has been
shown to actively reprogram these differentiated cells
into an induced pluripotent stem (iPS) cell state [2,
7–9]. It has been further demonstrated that pluripotency
can be induced without c-Myc, however, with lower
efﬁciency [10, 11]. This provides a manageable approach
to generate large quantities of human iPS cells for thera-
peutic purposes [12]. However, the low efﬁciency of this
iPS-generating process hinders the development of iPS
technology into clinical applications. Although multiple
methods have been attempted to enhance the iPS
process, such as adding SV40 large T antigen [13],
co-overexpressing MyoD [14], enhancing RA signaling
[15], or depleting Mdb3 that is a core component of the
NuRD complex [16], it remains largely unknown how
the iPS process is regulated by upstream signaling
pathways in vivo [17].
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tion of iPS technology is that all four transcription fac-
tors (Sox2, Oct4, Klf4, and c-Myc) are found to be
frequently overexpressed in various cancers [6]. Thus, it
is not surprising that a high percentage of mice derived
from iPS cells developed tumors [2]. Moreover, it is
noteworthy that the iPS process, which requires the
coexpression of four transcriptional factors, mirrors the
transformation of primary human cells, in which over-
expression of the Ha-Ras and hTERT oncogenes and
inactivation of both the p53 and Rb tumor suppressor
pathways by SV40 LT antigen are required [18, 19].
More interestingly, tumorigenesis and embryonic devel-
opment share many similarities. For example, both of
them are immortalized and could form tumors when
implanted subcutaneously in mice. There is also a grow-
ing body of evidence suggesting that many tumors arise
by acquiring genetic mutations in only a small popula-
tion of transformed cells termed cancer stem cells, or
cancer initiating cells [20–22]. As cancer stem cells are
more resistant to common chemotherapeutic interven-
tions, it is critical to understand their biological features
in order to develop better anticancer regimens [23, 24].
To this end, it has been proposed that cancer stem cells
were derived from either normal stem cells through
acquiring genetic mutations or terminally differentiated
somatic cells by activating a subset of genes typically
overexpressed in stem cells to acquire a stem cell-like
phenotype [24]. In this scenario, cellular transformation
correlates with the dedifferentiation process. Nonethe-
less, in both cases genetic mutations are a driving force
to cancer stem cell formation. Thus, acquiring muta-
tions that promote tumorigenesis might also partially
convert somatic cells into a stem cell-like phenotype
through pathways partially resembling the iPS process.
In support of this idea, recently it has been shown that
inactivation of the p53 tumor suppressor pathway
greatly enhanced iPS efﬁciency [25–29], suggesting that
key signaling pathway(s), frequently altered in human
cancers, might also be involved in stem cell mainte-
nance [30].
In addition to p53, the PTEN/PI3K/Akt pathway is
found commonly hyperactivated in various human
carcinomas through various means of genetic alterations
and is considered as a hallmark of cancer [31, 32]. In
support of a critical role for Akt in stem cell regulation,
constitutive activation of Akt was shown to be capable of
substituting for basic ﬁbroblast growth factor [33] or
leukemia inhibitory factor to maintain stemness. Consis-
tently, loss of PTEN is found to affect the hematopoietic
stem cell renewal process [34, 35]. However, further
in-depth evaluations revealed that PTEN negatively
regulated the mTORC2/Akt signaling only in adult, but
not neonatal hematopoietic stem cells [34]. This not only
highlighted a development stage-dependent role for PTEN
in maintaining stemness but also suggested a potential
temporal regulation difference between stem cell self-
renewal and tumorigenesis. However, even though Akt
has been characterized as a driving oncogene to facilitate
tumorigenesis, it remains largely elusive how Akt partici-
pates in stem cell fate regulation and whether similar to
its oncogenic role, Akt could enhance the efﬁciency of the
iPS process.
Methods
Plasmids
CMV-Flag-Sox2, CMV-Flag-Oct4, CMV-Flag-Klf4, and
CMV-Flag-Nanog were obtained from Addgene
(Cambridge, MA). pcDNA3-HA-p300, Myc-p300, and
pcDNA3-HA-CBP were obtained from Dr. James DeCa-
prio (Dana-Farber Cancer Institute, Boston, MA).
pcDNA3-HA-Myr-Akt1 construct was obtained from Dr.
Alex Toker (Beth Israel Deaconess Medical Center, Bos-
ton, MA) and described previously [36]. ERK1, p38-mito-
gen-activated protein kinase (MAPK), GSK3, and HA-
Fbw7 expression plasmids were described previously [37].
Various mutation constructs of Flag-Klf4, Flag-Oct4, and
Flag-Sox2 were generated using the QuikChange XL
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA)
according to the manufacturer’s instructions.
siRNAs
Scramble, luciferase, b-TRCP1+2, Fbw7, Skp2, and Cdh1
siRNA oligos and siRNA transfection methods have been
described previously [36].
Antibodies
Anti-b-catenin, Skp2, cyclin E, and polyclonal anti-HA
antibodies were purchased from Santa Cruz (Dallas, TX).
Anti-phospho-Akt substrate (RxRxxpS/T), acetylated-Lys,
and Klf4 antibodies were purchased from Cell Signaling
Technology (Danvers, MA). Anti-Tubulin and Vinculin
antibodies, polyclonal and monoclonal anti-Flag antibod-
ies, anti-Flag agarose beads, anti-HA agarose beads, and
anti-mouse and rabbit horseradish peroxidase-conjugated
secondary antibodies were purchased from Sigma (St.
Louis, MO). Monoclonal anti-HA antibody was pur-
chased from Covance (Princeton, NJ). Anti-GFP and
Cdh1 antibodies were purchased from Invitrogen (Carls-
bad, CA).
1212 ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Posttranslational Control of iPS-Inducing Factors X. Dai et al.Immunoblots and immunoprecipitation
Cells were harvested with EBC buffer (50 mmol/L Tris
pH 7.5, 120 mmol/L NaCl, 0.5% NP-40) containing
protease inhibitors (Roche, Indianapolis, IN) and phos-
phatase inhibitors (Calbiochem, Billerica, MA). Whole
cell lysates were subjected to immunoblot analyses with
indicated antibodies. Immunoprecipitations were carried
out by incubating 1 mg of whole cell lysates with 8 lL
of HA or Flag slurry beads (Sigma) for 3–4 h at 4°C.
Immunoprecipitants were washed ﬁve times with NETN
buffer (20 mmol/L Tris, pH 8.0, 100 mmol/L NaCl,
1 mmol/L ethylenediaminetetraacetic acid, and 0.5% NP-
40) and resolved by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) for immunoblot
analyses.
Cell culture and transfection
Cell culture and transfection procedures have been
described previously [36, 38]. For cell transfection, cells
were transfected using Lipofectamine (Life Technologies,
Woburn, MA) in OptiMEM medium (Life Technologies)
according to the manufacturer’s instructions. Forty-eight
hours posttransfection, transfected cells were further sub-
jected to immunoblot analysis.
Results
Oct4 and Klf4 are phosphorylated by Akt in
vivo
Consistent with previous reports [39, 40], we observed
that a constitutive active Akt (N-terminal tagged with a
myristoylation tag) could phosphorylate Oct4 in cells.
Furthermore, Klf4, in addition to Oct4, but not Sox2 or
Nanog, was also found phosphorylated by exogenous
Akt1 (Fig. 1A). By scanning the Oct4 protein sequence,
we identiﬁed an AGC kinase consensus motif “RxRxxpS/
pT” [41] located at the Thr235 residue (Fig. 1B) and
mutation of this site to a nonphosphorylatable residue,
Ala, almost completely abolished Akt1-mediated Oct4
phosphorylation (Fig. 1C). The critical function of Oct4
in stem cell regulation is mainly attributed to its role as a
transcriptional regulator, which is achieved by direct
binding of Oct4 to its canonical octamer motif through
its DNA-binding domains [42, 43]. Interestingly, Oct4
contains two distinct DNA-binding domains and it can
form either a homodimer with itself, or a heterodimer
with other transcription factors, depending on the oct-
amer half-sites present in the enhancer region of the tar-
get gene. Thus, it is interesting to investigate whether
phosphorylation of Oct4 potentially affects its ability to
form homodimers or heterodimers. To this end, we did
not observe a signiﬁcant effect of Akt-mediated Oct4
phosphorylation on Oct4 homodimer formation
(Fig. 1D). As generally Sox proteins require partners such
as other transcription factors for activation and previous
studies has demonstrated that Oct4 could form a complex
with Sox2 on DNA to control the expression of embry-
onic development-related genes [44–47], next we exam-
ined whether Oct4 phosphorylation on T235 affects its
interaction with Sox2. Interestingly, phosphorylation of
Oct4 signiﬁcantly reduced Oct4 interaction with Sox2
(Fig. 1D). Consistent with this result, ectopic expression
of Akt1 led to dissociation of Sox2 from wild-type Oct4
but not T235A Oct4 (Fig. 1E). These data suggest that
Akt-mediated phosphorylation of Oct4 on T235 might
regulate cellular stemness in a signal dependent manner
through modulating heterodimer formation with Sox2.
Notably, a recent study illustrated that phosphorylation of
Oct4 on T235 led to enhanced binding of Oct4 to Sox2
to differentially regulate transcription of stemness genes
[39]. The discrepancy between their observation and our
study might stem from different cell lines examined,
which might suggest that Akt-mediated phosphorylation
of Oct4 at T235 might regulate transcription of stemness
genes through modulating Oct4/Sox2 complex formation
in a cellular context-dependent manner, and warrants fur-
ther investigation. In addition, phosphorylation of Oct4
at S229 and Y327 has also been observed to have differen-
tial effects on its transcriptional activity toward multiple
targets [48]. Furthermore, Sox2 phosphorylation at T118
by Akt has also been reported to enhance the transcrip-
tional ability of Sox2 in ESCs by unknown mechanisms
[49]. Similarly, phosphorylation of Nanog was observed
in cell as well but has not been connected with any char-
acterized function [50].
Furthermore, we observed that in addition to Oct4,
Klf4 phosphorylation was also increased when co-overex-
pressed with Myr-Akt1 in cells (Fig. 1F). By truncating
Klf4 we narrowed down the Akt-mediated phosphoryla-
tion site(s) within amino acids 340–483, which contain
an evolutionarily conserved AGC consensus motif
located at T429. More importantly, mutation of Thr429
to Ala completely abolished the phosphorylation of the
C-terminal portion of Klf4 by Akt (Fig. 1F and G). As
Klf4 could directly interact with the Oct4/Sox2 complex
to facilitate somatic cell reprogramming [51], it is plau-
sible that phosphorylation of Klf4 at T429, which resides
in its zinc ﬁnger motif, might participate in modulating
cellular stemness by affecting its interaction with the
Oc4/Sox2 complex. Interesting, recent work has clearly
demonstrated the critical role for Oct4 in pluripotency
regulation, while Klf4 could be substituted by other fac-
tors [8, 52], therefore we hypothesize that Akt controls
ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 1213
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phosphorylation of Oct4, or by shifting Oct4-binding
partners. Taken together, these results indicate that
Akt-mediated phosphorylation might be an upstream
regulatory mechanism responsible for the formation of
iPS cells.
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Figure 1. Oct4 and Klf4 are phosphorylated by Akt in vivo. (A) Immunoblot (IB) analysis of whole cell lysates (WCLs) and immunoprecipitates (IPs)
derived from 293T cells transfected with HA-tagged Myr-Akt1 and indicated Flag-tagged constructs. Akt-mediated phosphorylation was
recognized by an Akt substrate-motif phosphorylation-speciﬁc antibody (RxRxxpS/pT). (B) Sequence alignment of the Thr235 putative Akt
phosphorylation site in Oct4 among different species. (C) Akt speciﬁcally phosphorylated Oct4 at Thr235. (D) Phosphomimetic mutation at Thr235
of Oct4 decreased Oct4 interaction with Sox2. IB analysis and Flag-IP derived from 293T cells transfected with indicated constructs. (E)
Phosphorylation of Oct4 on Thr235 led to attenuated Oct4 interaction with Sox2. WCLs of 293T cells transfected with indicated constructs were
subjected to immunoprecipitation with Flag antibody. The Flag-IPs and WCLs were immunoblotted with indicated antibodies. (F) Akt
phosphorylated Klf4 at Thr399. WCLs of 293T cells transfected with indicated constructs were subjected to immunoprecipitation with Flag
antibody. The Flag-IPs and WCLs were immunoblotted with indicated antibodies. (G) Sequence alignment of the Thr429 putative Akt
phosphorylation site in Klf4 among different species.
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in vivo
In addition to phosphorylation, various posttranslational
modiﬁcations have been demonstrated as regulatory
mechanisms in controlling the transcriptional activities of
Oct4, Sox2, Klf4, and Nanog. For example, SUMOylation
of Oct4 or Sox2 has been observed but with opposite
effects on protein function. Speciﬁcally, Oct4 SUMOyla-
tion led to enhanced stability and DNA-binding ability
[53], while Sox2 SUMOylation resulted in attenuated
DNA-binding ability [54]. As Akt has been demonstrated
to modulate protein acetylation process by direct phos-
phorylation of the acetyl-transferases p300 [55] or CBP
[56], next we examined whether any of the four iPS fac-
tors, Oct4, Sox2, Klf4, or Nanog, were subjected to acety-
lation-mediated regulation. From our initial screening by
coexpression of an iPS factor with either p300 or CBP in
cells, we observed various acetylation patterns among
these iPS factors. First, p300- or CBP-dependent acetyla-
tion of Nanog was not detected in our experimental con-
dition by an Ac-K antibody (Fig. 2A). Second, Sox2
displayed a high level of basal acetylation and a slight
increase in acetylation in the presence of ectopic p300 or
CBP (Fig. 2A). Third, acetylation of both Oct4 and Klf4
was induced by p300-WT but not with a p300-acetyl-
transferase dead mutant, or CBP (Fig. 2A). Interestingly,
ectopic expression of Akt1 induced the acetylation of
Klf4, but not Sox2, Oct4, or Nanog (Fig. 2B), suggesting
that the Akt activity directly and/or indirectly regulates
acetylation state of iPS factors in a different mechanism.
More importantly, p300-mediated acetylation of Oct4/
Sox2 led to a dramatically decreased interaction between
Sox2 and Oct4 (Fig. 2C), suggesting that acetylation of
Oct4/Sox2 behaves similarly to Oct4 phosphorylation-
mediated impairment of the association between Oct4
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Figure 2. Oct4 and Klf4 are acetylated by p300 in vivo. (A) Whole cell lysates (WCLs) of 293T cells transfected with HA-tagged p300 or CBP
with indicated Flag-tagged constructs were subjected to immunoprecipitation (IP) with Flag antibody. The Flag-IPs and WCLs were immunoblotted
with indicated antibodies. Acetylation was detected by a Lys-acetylation (Ac-K) antibody. (B) WCLs of 293T cells transfected with indicated
constructs were subjected to immunoprecipitation with Flag antibody. The Flag-IPs and WCLs were immunoblotted with indicated antibodies. (C)
WCLs of 293T cells transfected with indicated constructs were subjected to immunoprecipitation with HA antibody. The HA-IPs and WCLs were
immunoblotted with Flag and HA antibodies.
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scription activity of Oct4 toward a certain subset of genes
[46, 47].
Sox2 is acetylated by p300 on multiple sites
in vivo
To obtain mechanistic insights into how acetylation of
Sox2 and Oct4 modulate their complex formation, we
tried to pinpoint the acetylation sites on both Sox2 and
Oct4. As Sox2 displayed both basal and p300-dependent
acetylation events (Fig. 2A), we ﬁrst truncated Sox2 to
narrow down the possible acetylation region(s) (Fig. 3A).
Interestingly, all truncations missing the ﬁrst 1–48 amino
acids showed dramatically reduced acetylation signals
(Fig. 3B), suggesting that the major basal Sox2 acetylation
sites are located within the ﬁrst 48 amino acids. As the
HMG domain is the critical functional module for Sox2
function and there are two lysine residues (K37 and K44)
located within this critical region, we further examined
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Posttranslational Control of iPS-Inducing Factors X. Dai et al.whether these two sites were the acetylation targets. Nota-
bly, mutation of K37, K44, or both sites to Arg to abolish
possible acetylation did not signiﬁcantly affect the basal
acetylation state of Sox2 (Fig. 3C), indicating that neither
K37 nor K44 is the major acetylation site. In addition to
K37 and K44, there is only one lysine, K10, left in the
ﬁrst 48 amino acids, thus it warrants further investigation
to pinpoint whether K10 is the major site for Sox2 basal
acetylation. Furthermore, for p300-dependent Sox2
acetylation, multiple sites might be involved, as a series of
truncations displayed a gradual decrease in Sox2 acetyla-
tion (Fig. 3D). One of these acetylation events on K75
has been recently reported to be critical to export Sox2 to
the cytoplasm to terminate its transcriptional activity in
the nucleus [57], which is consistent with our model that
p300-mediated acetylation on Sox2/Oct4 impairs their
ability to transcribe downstream genes.
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in cells
Similarly, we constructed a series of Oct4 truncation
mutants to further map the acetylation sites on Oct4
(Fig. 4A). In cells we observed that the acetylation sites
were mainly located within amino acids 220–233
(Fig. 4B), while the major p300 interacting motif was
mapped within amino acids 140–163 (Fig. 4C). As the
POU and Homeodomain serve as a bipartite DNA-bind-
ing domain in Sox2 (Fig. 4A), and part of the POU and
HM domains are located within these two regions, we
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ine which lysine was critical for Oct4 acetylation. Notably,
all single KR mutation tested exhibited attenuated Oct4
acetylation status (Fig. 4D), indicating that p300-medi-
ated Oct4 acetylation occurs on multiple sites [16, 58],
which has been reported in many of p300 downstream
substrates. Nevertheless, Oct4 and Sox2 acetylation led to
impaired Oct4/Sox2 heterodimer formation (Fig. 2C) and
subsequent attenuated transcriptional activity [46, 47].
Klf4 is acetylated by p300 on multiple sites
in cells
Furthermore, we generated Klf4 truncation mutations to
pinpoint its p300-dependent acetylation site(s) (Fig. 5A).
By this method, we narrowed down the Klf4 acetylation
sites to amino acids 1–151 (Fig. 5B) and further to 25–
151 (Fig. 5C). Notably, a previous report indicated that
p300 mainly acetylated Klf4 on K225 and K229 to
enhance its transcriptional activity [59]. However, in our
experimental system, mutation of both K225 and K229 to
Arg did not signiﬁcantly reduce Klf4 acetylation status
(Fig. 5C), suggesting that there might be other sites
involved in p300-mediated acetylation of Klf4. Consistent
with this notion, we identiﬁed two lysine residues within
amino acids 24–151, K32 and K52, that were possible
acetylation sites (Fig. 5D). However, mutating K52 to
arginine did not noticeably affect Klf4 acetylation,
suggesting that K32 or both K32 and K52 are possible
p300 acetylation targets (Fig. 5D) that warrant further
investigation.
Fbw7 possibly governs Klf4 stability in a
GSK3-dependent manner
During our examination of Klf4 acetylation, consistent
with a previous report that Klf4 was subjected to 26S pro-
teasome-mediated degradation [60], we observed that
Klf4 was unstable. However, its upstream E3 ligases
remain largely unknown. To this end, we screened a panel
of E3 ligases for their possible roles in governing Klf4 sta-
bility by various siRNAs (Fig. 6A). Interestingly, com-
pared to the mock treatment, only depletion of Fbw7, but
not other E3s examined, led to an accumulation of Klf4
(Fig. 6A). The regulation of Klf4 by Fbw7 is further con-
ﬁrmed by the Fbw7 knockdown experiment with multiple
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characterized that Fbw7 only recognizes substrates with
proper posttranslational modiﬁcations [61, 62], next we
attempted to identify its possible upstream modifying
kinase(s). To this end, we observed that coexpression with
GSK3, but neither ERK1 nor p38-MAPK, resulted in an
efﬁcient degradation of Klf4 (Fig. 6C), and depletion of
GSK3b led to accumulation of Klf4 (Fig. 6D), demon-
strating that GSK3 is a major upstream kinase responsible
for Klf4 turnover mediated by Fbw7. This is consistent
with a previous report that activation of the Akt pathway
by peroxisome proliferator-activated receptor gamma ago-
nist could stabilize Klf4 by reducing its ubiquitination
[63]. As phosphorylation of GSK3 by Akt can inactivate
its kinase activity [64], which could lead to reduced Klf4
phosphorylation by GSK3, therefore evading Fbw7-medi-
ated proteolysis. Through a close examination of the Klf4
protein sequence, we identiﬁed two putative Fbw7 con-
sensus degrons [61] on Klf4 (Fig. 6E) that are evolution-
arily conserved (Fig. 6F), which further supports Klf4 as a
possible Fbw7 substrate and warrants further investiga-
tions.
Discussion
Recent scientiﬁc advances have demonstrated that tumors
arise in a step-wise fashion through gain-of-function
mechanisms from certain oncogenes, concomitantly with
the loss of expression of key tumor suppressor proteins
[65, 66]. In addition to the p53 tumor suppressor path-
way that is inactivated in about 50% of all human can-
cers, hyperactivation of the PTEN/PI3K/Akt pathway was
observed in over 40% of human carcinomas [67, 68].
Recent work indicates that PTEN is directly linked to the
hematopoietic stem cell renewal process [69, 70]. Further-
more, it is well established that mouse stem cells are com-
mitted to differentiation after withdrawal of the LIF
ligand, indicating that a yet unknown downstream signal
transduction pathway triggered by LIF is critical to main-
tain the stem cell state. Surprisingly, constitutive activa-
tion of Akt was shown to adequately substitute the
function of LIF [71]. However, it remains unclear how
constitutive activation of Akt signaling is sufﬁcient to
maintain pluripotency.
Oct4, Sox2, and Klf4 co-occupy a substantial portion
of their downstream target genes to build up a regulatory
circuit consisting of multiple autoregulatory and feed-for-
ward loops. In this scenario, it creates consistent activity
above a threshold level to maintain the pluripotent state,
while the whole system is unstable, and might quickly
shut down when one critical regulator becomes negative
[72, 73]. To this end, we observed that Akt directly phos-
phorylated key transcriptional factors including Oct4 and
Klf4 to restrict their activities below this threshold. These
results also indicate that Akt-mediated phosphorylation
might be an upstream regulatory mechanism responsible
for the formation of iPS cells (Fig. 7). Therefore, it will
be intriguing to examine whether coexpression of Myr-
Akt (an active form of Akt) together with Sox2, Oct4,
and Klf4 will greatly enhance the efﬁciency of iPS forma-
tion. Furthermore, whether point mutations of all the
potential Akt sites in Oct4 or Klf4 would attenuate this
phenotype.
In addition to a direct role of Akt-mediated phosphor-
ylation of iPS factors in regulating the iPS process, Akt
could also indirectly affect stemness by modulating other
posttranslational modiﬁcations of iPS factors. To this
end, we have identiﬁed that Akt could either facilitate
p300-mediated acetylation of Oct4, Sox2, and Klf4 by
directly activating p300, or stabilizing Klf4 by directly
phosphorylating and inactivating GSK3 to evade Fbw7-
mediated degradation of Klf4 (Fig. 7). Consistently, mul-
tilayer regulations of iPS factors have been identiﬁed to
cooperatively regulate the pluripotency. For example, a
chemical agent ATRA has been shown to increase the
interaction of Klf4 with p300 by inducing Klf4 phosphor-
ylation via activation of c-Jun N-terminal kinase and p38
Klf4 
Oct4 
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Klf4 
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P
Ac
Akt
p300
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?
Figure 7. A schematic model for how Akt mediates the induced
pluripotent stem (iPS) process through direct or indirect regulation of
posttranslational modiﬁcations of iPS-inducing factors. Akt directly
phosphorylates Oct4 to modulate its interaction with Sox2, leading to
a shift of Oct4/Sox2-mediated transcription events. Akt may also
activate p300 to promote acetylation of Oct4, Sox2, and Klf4 at
multiple sites to change their transcription activity. Furthermore, Akt
phosphorylates GSK3, resulting in reduced Klf4 phosphorylation by
GSK3 that could possibly trigger Fbw7-mediated degradation of Klf4.
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its activity to transactivate the Mfn-2 promoter [74].
Since Oct4, Sox2, and Klf4 were found to be key regula-
tors of stem cells, it is possible that Akt could directly or
indirectly modulate their transcriptional activities, thus
inﬂuencing the maintenance of pluripotency.
As cellular reprogramming and the carcinogenic pro-
cess share many similar features and mechanisms [75,
76], it is not surprising that these iPS markers might
play critical roles in tumorigenesis as well. To this end,
overexpression of Sox2 [77–79] or Oct4 [80–82] has
been observed in multiple cancer types. Similarly, Klf4
overexpression was observed to promote malignant
transformation through downregulation of the Cdk
inhibitor p21 [83]. Klf4 belongs to the family of Krup-
pel-like transcription factors, whose functions have been
implicated in regulation of tissue-speciﬁc development
[84]. Elevated Klf4 overexpression is frequently observed
in many types of cancers [85] and overexpressing Klf4
in mice led to squamous cell cancer [86], while the
molecular mechanisms remain unclear. However, on the
other hand, recent studies demonstrated that rather than
an oncogene, Klf4 serves as an inhibitor for tumor cell
growth and migration [85, 87, 88]. Interestingly, loss of
Fbw7 is frequently found in T-cell acute leukemia (T-
ALL), a disease caused by the blockage of proper differ-
entiation from progenitor cells to mature T cells. In this
study, we found that Fbw7 could possibly degrade Klf4
in a GSK3-dependent manner. As a result, loss of Fbw7
could cause accumulation of the Klf4 transcription fac-
tor, which might subsequently block the proper differen-
tiation process, leading to the development of leukemia.
Taken together, our study provided insight into the criti-
cal role of the Akt oncogenic pathway in regulating stem
cell reprogramming and impact on the cancer stem cells.
Thus, it will provide the rationale, therefore opening
new avenues for developing Akt-speciﬁc inhibitors as
efﬁcient anticancer drugs.
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